On the Management of Metastatic Prostate Cancer with LH-RH Analogs

  • J. H. M. Blom
  • F. H. Schröder
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 124)


With the availability of luteinizing hormone releasing hormone (LH-RH) agonists, and in the future of maybe also of LH-RH antagonists, new principles were introduced into the clinical management of human prostate carcinoma and other steroid-hormone-dependent tumors (Schröder et al. 1987). LH-RH agonists offered a new principle of suppressing testicular androgen to castration levels, the major advantage of which over the classical forms of treatment with estrogen administration or castration seemed to be an absence of physical side effects and a reduction of physiological side effects. For these advantages a much higher price has to be paid, and it now remains questionable in how far LH-RH agonists will be able to compete with other principles of castration in the management of this disease.


Advanced Prostate Cancer Metastatic Prostate Cancer Plasma Testosterone Luteinizing Hormone Release Hormone LHRH Agonist 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alcini E, D’Addessi A, Destito A, Grasso G (1988) LH-RH analogue treatment for advanced prostate cancer. Am J Clin Oncol 11 [Suppl 2]:S120–S122PubMedCrossRefGoogle Scholar
  2. Blom JHM, Hirdes WH, Schröder FH, De Jong FH, Kwekkeboom DJ, van Veen AJ, Sandow J, Krauss B (1989) Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 17:43–46PubMedCrossRefGoogle Scholar
  3. Brisset J-M, Boccon-Gibod L, Botto H, Camey M, Cariou G, Duclos J-M, Duval F, Gonties D, Jorest R, Lamy L, LeDuc A, Mouton A, Petit M, Prawerman A, Richard F, Sava-tovsky I, Vallancie G (1987) Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New YorkGoogle Scholar
  4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424PubMedCrossRefGoogle Scholar
  5. Debruyne F (1989) Luteinizing hormone-releasing hormone analogues alone in the treatment of advanced disease. Horm Res 32 [Suppl 1]: 62–65PubMedCrossRefGoogle Scholar
  6. Debruyne FMJ, Denis L, Lunglmayr G, Mahler C, Newling DWW, Richards B, Robinson MRG, Smith PH, Weil EHJ, Whelan P (1988) Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma. J Urol 140:775–777PubMedGoogle Scholar
  7. Denis L (1989) LHRH analogues in combination with an anti-androgen in the treatment of advanced disease. Horm Res 32 [Suppl 1]:66–68PubMedCrossRefGoogle Scholar
  8. Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho APA, Newling D, Bono A, Sylvester R, De Pauw M, Vermeylen K, Ongena P and members of the EORTC GU group (1990) Complete androgen blockade: data from an EORTC 30853 trial. Sem Urol 8:166–174Google Scholar
  9. Decensi AU, Guarneri D, Marroni P, Cristina L, Paganuzzi M, Boccardo F (1989) Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men. J Urol 142:1235–1238PubMedGoogle Scholar
  10. De Sy WA, De Meyer JM, Casselman J, De Smet R, Renders G, Schelfhout W, De Wilde P (1986) A comparative study of a long acting luteinizing hormone releasing hormone agonist (decapeptyl) and orchiectomy in the treatment of advanced prostatic cancer. Acta Urol Belg 54:221–229PubMedGoogle Scholar
  11. Grant JBF, Ahmed SR, Shake SM, Costello CB, Howell A, Blacklock NJ (1986) Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy. Br J Urol 58:539–544PubMedCrossRefGoogle Scholar
  12. Habenicht UF, Witthaus E, Neumann F (1986) Antiandrogens and LH-RH agonists endocrinology in the initial phase of their use. Akt Urol 17:10–16CrossRefGoogle Scholar
  13. Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, Klarskov P, Kramp T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H (1990) A phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66:1058–1066PubMedGoogle Scholar
  14. Jones WG, Fossá SD, Bono A, Croies JJ, Stoter G, De Pauw M, Sylvester R, members of the EORTC Gentourinary Tract Cancer Cooperative Group (1986) Mitimycin-C in the treatment of metastatic prostate cancer: report on an EORTC phase II study. World J Urol 4:182–185CrossRefGoogle Scholar
  15. Kotake T, Usami M, Sonoda T, Matsuda M, Okajima E, Osafune M, Isurugi K, Akaza H, Saitoh Y (1988) LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S1O8–S111CrossRefGoogle Scholar
  16. Koutsilieris M, Faure N, Tolis G, Laroche B, Robert G, Ackman CFD (1986) Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either buserelin or orchiectomy. Urology 27:221–228PubMedCrossRefGoogle Scholar
  17. Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis J-F, Costa P, Husson J-M, Dahan R, Bertagna C, Edelstein R (1989) Prevention of the transient edverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321:413–418PubMedCrossRefGoogle Scholar
  18. Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4:579–594PubMedCrossRefGoogle Scholar
  19. Labrie F, Dupont A, Belanger A (1985) Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833–841PubMedCrossRefGoogle Scholar
  20. Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacoursiere Y, Emond J, Monfette G (1986) Treatment of prostate cancer with gonadotropin-relasing hormone agonists. Endocr Rev 7:67–74PubMedCrossRefGoogle Scholar
  21. Leuprolide Study Group (1984) Leuprolide versus Diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281–1286CrossRefGoogle Scholar
  22. Mahler C, Denis L (1988) Simultaneous administration of a luteinizing hormone releasing hormone agonist and diethylstilbestrol in the initial treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S127–S128PubMedCrossRefGoogle Scholar
  23. Manni A, Santen RJ, Boucher AE, Lipton A, Harvey H, Simmonds M, White-Hershey D, Gordon RA, Rohner T, Drago J (1986) Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trial. Anticancer Res 6:309–314PubMedGoogle Scholar
  24. Mauriac L, Coste P, Richaud P, Lamarche P, Mage P, Bonichon F (1988) Clinical study of an LH-RH agonist (ICI 118630, Zoladex) in the treatment of prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S117–S119PubMedCrossRefGoogle Scholar
  25. Metz R, Namer M, Adenis L, Audhuy B, Bugat R, Colombel P, Couette JE, Grise P, Khater R, LePorz B, Levin G, Marti P, Mauriac M, Rouxel A, Tetelboum R (1988) Zoladex as primary therapy in advanced prostatic cancer. Am J Clin Oncol 11 [Suppl 2]:S112–S114PubMedCrossRefGoogle Scholar
  26. Navratil H (1987) Double-blind study of Anandron versus placebo in Stage D2 prostate cancer patients receiving buserelin. Results in 49 cases from a multicentre study. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New YorkGoogle Scholar
  27. Neri R, Florance K, Koziol P, Van Cleave S (1972) A biological profile of a nonsteroidal antiandrogen, Sch 13521 (4′-nitro-3′-trifluoromethylisobutyranalide). Endocrinology 91:427–437PubMedCrossRefGoogle Scholar
  28. Oesterling JE, Epstein JI, Walsh PC (1986) The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypog-onadism and panhypopituitarism. J Urol 136:1030–1034PubMedGoogle Scholar
  29. Parmar H, Lightman SL, Allen L, Phillips RH, Edwards L, Schally AV (1985) Randomised controlled study of orchiectomy vs long-acting D-Trp6-LHRH microcapsules in advanced prostatic carcinoma. Lancet 30:1201–1205CrossRefGoogle Scholar
  30. Parmar H, Edwards L, Phillips RH, Allen L, Lightman SL (1987) Orchiectomy versus long-acting D-Trp6-LHRH in advanced prostatic cancer. Br J Urol 59:248–254PubMedCrossRefGoogle Scholar
  31. Petersson F, Hammar M, Mathson K, Hjertberg H, Varenhorst E (1987) Influence of continuous luteinizing hormone-releasing hormone agonist on steroidogenic enzymes in the human testis. Scand J Urol Nephrol 21:267–271PubMedCrossRefGoogle Scholar
  32. Poyet P, Labrie F (1985) Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone actetate and megestrol acetate. Mol Cell Endocrinol 42:283–288PubMedCrossRefGoogle Scholar
  33. Robinson MRG, Hetherington J (1986) The EORTC studies: is there an optimal endocrine management for Ml prostatic cancer? World J Urol 4:171–175CrossRefGoogle Scholar
  34. Roger M, Duchier J, Lahlou N, Nahoul K, Schally AV (1985) Treatment of prostatic carcinoma with D-Trp6-LH-RH: plasma hormone levels after daily subcutaneous injections and periodic administration of delayed-release preparations. Prostate 7:271–282CrossRefGoogle Scholar
  35. Sandow J, Beier B (1985) LHRH agonists: mechanism of action and effect on target tissues. Prog Clin Biol Res 185A:121–142PubMedGoogle Scholar
  36. Schröder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, De Jong FH, Klijn JGM, Matroos AW, De Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acatate. J Urol 137:912–918Google Scholar
  37. Schulze H, Senge T (1990) Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carinoma of the prostate. J Urol 144:934–941PubMedGoogle Scholar
  38. Schulze H, Isaacs J, Senge T (1987) Inability of complete androgen blockade to increase survival of patients with advanced prostatic cancer as compared to standard hormonal therapy. J Urol 137:909–911PubMedGoogle Scholar
  39. Sharifi R, Soloway M, The Leuprolide Study Group (1990) Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol 143:68–71PubMedGoogle Scholar
  40. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD (1973) Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45:668–677PubMedCrossRefGoogle Scholar
  41. Thompson IM, Zeidman EJ, Rodriguez FR (1990) Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 144:1479–1480PubMedGoogle Scholar
  42. Waxman JH, Sandow J, Man A, Barnett MJ, Hendry WF, Besser GM, Oliver RTD, Magill PJ (1986) The first clinical use of depot buserelin for advanced prostatic carcinoma. Cancer Chemother Pharmacol 18:174–175PubMedCrossRefGoogle Scholar
  43. Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O’Donoghue EPN, Sikora K (1988) The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-re-leasing hormone analogue. Am J Clin Oncol 11 [Suppl 2]:S152–S155PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • J. H. M. Blom
    • 1
  • F. H. Schröder
    • 1
  1. 1.Department of UrologyErasmus UniversityRotterdamThe Netherlands

Personalised recommendations